Lithera Reports Positive Phase IIa Clinical Study Results for LIPO-102, a Novel Treatment for Localized Fat Reduction

Published: Mar 09, 2010

SAN DIEGO, March 9, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction. LIPO-102 is being studied for the treatment of exophthalmos using abdominal fat as a surrogate for periorbital fat. LIPO-102 was well-tolerated when administered weekly for 4 weeks into the subcutaneous abdominal fat of healthy subjects. Dose- and time-related reductions in abdominal circumference and skin-fold thickness measures were observed one (Week 5) and four (Week 8) weeks after the treatment period. A reduction of 3.47 cm (p=0.017) in mean abdominal circumference was observed at Week 8 in subjects receiving the optimal dose of LIPO-102 once per week for 4 weeks.

Back to news